New drug offers hope for advanced pancreatic cancer

In a historic milestone for oncology, the us food and drug administration (FDA) has granted expedited approval to Daraxonrasib (marketed as rasonque by revolution medicines), marking the first-ever approved targeted therapy to successfully tackle the "undruggable" ras protein mutations that drive over 90% of pancreatic cancers.